Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07093411 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

StatusRecruiting
PhaseEarly Phase 1
Started2025-08-05
View on ClinicalTrials.gov ↗

Amendment history

2025-08-15
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-08→confirmed 2025-08-05
Study sites0→3
2025-07-23
minor
Original filing
A phase I, open-label clinical study to evaluate the safety, tolerability, and efficacy of LUCAR-E9D,LUCAR-E9K, a dual-targeted cell preparation targeting CD19/CD20, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Trial Details
NCT Number NCT07093411
Lead Sponsor Beijing GoBroad Hospital
Collaborators: First Affiliated Hospital of Wenzhou Medical University, The First Affiliated Hospital of Zhengzhou University, The Affiliated Hospital of Xuzhou Medical University, Second Affiliated Hospital of Xi'an Jiaotong University, Anhui Provincial Hospital
Conditions B-cell Non-Hodgkin Lymphoma Recurrent B-cell Non-Hodgkin Lymphoma Refractory
Enrollment 48 participants
Start Date 2025-08-05
Primary Completion 2028-08 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-20